Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Thermo Fisher Scientific Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Turnover Ratios
Inventory turnover 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Receivables turnover 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Payables turnover 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Working capital turnover 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Average No. Days
Average inventory processing period 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Add: Average receivable collection period 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Operating cycle 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Less: Average payables payment period 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Cash conversion cycle 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The short-term operating activity ratios demonstrate varied trends over the observed period. Generally, the company exhibits efficient inventory and receivable management, alongside a dynamic payables cycle. Fluctuations in working capital turnover suggest shifts in operational efficiency and potentially, strategic changes in working capital management.

Inventory Management
Inventory turnover generally increased from 3.87 to a peak of 5.06 before stabilizing around 4.85. This indicates improving efficiency in converting inventory into sales. The average inventory processing period correspondingly decreased from 94 days to 75 days, confirming faster inventory movement. A slight increase is observed in the most recent periods, suggesting a potential slowdown in sales or a build-up of inventory.
Receivables Management
Receivables turnover remained relatively stable, fluctuating between 5.13 and 5.76. The average receivable collection period remained consistently around 66-70 days, indicating consistent credit and collection policies. A slight lengthening of the collection period is noted towards the end of the period, potentially warranting further investigation.
Payables Management
Payables turnover exhibited more volatility, peaking at 10.82 before declining to 7.27. The average payables payment period decreased from 46 days to a low of 34 days, then increased to 50 days. This suggests the company initially improved its ability to manage supplier payments, potentially leveraging early payment discounts, but subsequently extended payment terms, possibly to conserve cash.
Working Capital Management
Working capital turnover experienced significant fluctuations, rising dramatically to 10.13 before declining to 3.30. This suggests substantial changes in the relationship between current assets and current liabilities. The decline in recent periods could indicate slower sales growth relative to working capital investment, or a deliberate strategy to build up working capital reserves.
Overall Operating Cycle & Cash Conversion Cycle
The operating cycle generally decreased from 164 days to 142 days, then increased to 156 days, reflecting changes in inventory and receivables management. The cash conversion cycle followed a similar pattern, decreasing from 118 days to 97 days, then increasing to 112 days, and finally decreasing to 98 days. These cycles are influenced by the combined effects of inventory processing, receivable collection, and payable payment periods. The recent trends suggest a potential lengthening of the cash conversion cycle, which could indicate a need to optimize working capital management.

In summary, the company demonstrates generally efficient short-term operating activity, but recent periods show signs of potential shifts in these efficiencies. Monitoring these trends closely will be crucial for maintaining optimal working capital management and overall financial health.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Thermo Fisher Scientific Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Cost of revenues 7,204 6,539 6,446 6,129 6,573 6,270 6,194 6,140 6,493 6,258 6,436 6,570 6,844 6,375 6,371 6,354
Inventories 5,425 5,745 5,559 5,224 4,978 5,430 5,198 5,133 5,088 5,404 5,655 5,664 5,634 5,722 5,668 5,483
Short-term Activity Ratio
Inventory turnover1 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Johnson & Johnson 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Vertex Pharmaceuticals Inc. 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Inventory turnover = (Cost of revenuesQ4 2025 + Cost of revenuesQ3 2025 + Cost of revenuesQ2 2025 + Cost of revenuesQ1 2025) ÷ Inventories
= (7,204 + 6,539 + 6,446 + 6,129) ÷ 5,425 = 4.85

2 Click competitor name to see calculations.


Inventory turnover exhibited an overall increasing trend throughout the observed period, with some fluctuations. Initially, the ratio demonstrated growth from 3.87 to 4.60 between April 2022 and December 2022. This initial increase suggests improving efficiency in managing inventory levels relative to cost of revenues. The ratio then stabilized, fluctuating between 4.57 and 5.06 from April 2023 to December 2024. A slight decline to 4.47 was observed in September 2025, followed by a recovery to 4.85 by the end of the period.

Overall Trend
The inventory turnover ratio generally increased over the analyzed timeframe. The ratio moved from 3.87 in April 2022 to 4.85 in December 2025, indicating a more efficient utilization of inventory. However, the rate of increase slowed considerably after December 2022.
Peak Performance
The highest inventory turnover ratio was recorded at 5.06 in both December 2022 and December 2024. These periods represent the most efficient inventory management within the observed timeframe, suggesting a strong alignment between inventory levels and sales activity.
Recent Fluctuations
A minor dip in inventory turnover was noted in September 2025 (4.47), representing the lowest value in the latter half of the period. This decrease could be attributed to a temporary build-up in inventory or a slowdown in sales during that quarter. The subsequent increase in December 2025 suggests this was a short-term anomaly.
Cost of Revenues & Inventory Relationship
Cost of revenues generally increased over the period, from US$6,354 million in April 2022 to US$7,204 million in December 2025. While inventories also fluctuated, the inventory turnover ratio’s increase indicates that cost of revenues grew at a faster rate than inventory levels, demonstrating improved inventory management effectiveness.

The observed trends suggest a generally positive performance in inventory management. The company appears to be effectively converting inventory into sales, although recent fluctuations warrant continued monitoring to ensure sustained efficiency.

AI Ask an analyst for more


Receivables Turnover

Thermo Fisher Scientific Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Revenues 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Accounts receivable, less allowances 8,900 8,911 8,594 8,455 8,191 8,255 7,943 7,931 8,221 8,370 8,019 7,922 8,115 7,671 7,745 7,889
Short-term Activity Ratio
Receivables turnover1 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Johnson & Johnson 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Vertex Pharmaceuticals Inc. 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Receivables turnover = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Accounts receivable, less allowances
= (12,215 + 11,122 + 10,855 + 10,364) ÷ 8,900 = 5.01

2 Click competitor name to see calculations.


The receivables turnover ratio exhibits a generally stable pattern over the analyzed period, with some fluctuations. Initially, the ratio demonstrated an increasing trend from April 2022 to October 2022, followed by a period of relative stability and then a slight decline towards the end of 2023. More recently, the ratio has shown some volatility, with a slight increase in the most recent period.

Overall Trend
The receivables turnover ratio generally remained within a narrow range of approximately 4.91 to 5.76 throughout the observed timeframe. This suggests consistent efficiency in collecting receivables, although with some quarterly variations.
Initial Increase (Apr 2, 2022 – Oct 1, 2022)
The ratio increased from 5.21 in April 2022 to 5.76 in October 2022. This indicates an improved ability to convert accounts receivable into cash during this period, potentially due to more effective credit and collection policies or a change in customer payment terms.
Subsequent Stability and Decline (Oct 1, 2022 – Sep 30, 2023)
Following the peak in October 2022, the ratio experienced a slight decline, fluctuating between 5.13 and 5.53. While remaining relatively stable, this suggests a potential slowing in the rate of receivables collection compared to the earlier part of the period. The ratio reached its lowest point of 5.13 in September 2023.
Recent Volatility (Dec 31, 2023 – Jun 28, 2025)
The ratio showed increased fluctuation in the most recent periods. It rose to 5.23 in December 2023, then decreased to 5.03 in March 2025, before increasing again to 5.01 in December 2025. This recent volatility could be attributed to seasonal sales patterns, changes in the customer mix, or adjustments to credit policies. The latest value, 5.01, is slightly below the average for the entire period.
Relationship to Revenues
While the receivables turnover ratio fluctuated, it generally remained consistent despite variations in revenue. Revenues decreased from US$11,818 million in April 2022 to US$10,345 million in April 2023, and then increased to US$12,215 million in December 2025. The relatively stable receivables turnover ratio suggests that changes in revenue did not significantly impact the efficiency of receivables collection.

In conclusion, the receivables turnover ratio indicates a generally consistent level of efficiency in managing accounts receivable. The observed fluctuations warrant further investigation to determine the underlying causes and potential implications for cash flow management.

AI Ask an analyst for more


Payables Turnover

Thermo Fisher Scientific Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Cost of revenues 7,204 6,539 6,446 6,129 6,573 6,270 6,194 6,140 6,493 6,258 6,436 6,570 6,844 6,375 6,371 6,354
Accounts payable 3,622 3,120 2,980 3,049 3,079 2,606 2,547 2,555 2,872 2,508 2,423 2,798 3,381 2,471 2,586 2,667
Short-term Activity Ratio
Payables turnover1 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Johnson & Johnson 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Vertex Pharmaceuticals Inc. 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Payables turnover = (Cost of revenuesQ4 2025 + Cost of revenuesQ3 2025 + Cost of revenuesQ2 2025 + Cost of revenuesQ1 2025) ÷ Accounts payable
= (7,204 + 6,539 + 6,446 + 6,129) ÷ 3,622 = 7.27

2 Click competitor name to see calculations.


The payables turnover ratio exhibits fluctuations over the observed period, generally indicating changes in the efficiency with which the company manages its accounts payable relative to its cost of revenues. An initial upward trend is followed by periods of decline and stabilization.

Overall Trend
The payables turnover ratio demonstrates variability across the quarters. It begins at 7.96 and generally increases through the first half of 2023, peaking at 10.82. Subsequently, the ratio declines, reaching a low of 7.27 before showing some recovery in the most recent period.
Initial Increase (Apr 2, 2022 – Jul 1, 2023)
From April 2022 to July 2023, the payables turnover ratio increased from 7.96 to 10.82. This suggests an improved ability to pay suppliers quickly during this timeframe, potentially due to more efficient procurement processes or strategic negotiations with vendors. The increase could also be linked to a faster rate of inventory turnover and sales.
Subsequent Decline (Sep 30, 2023 – Dec 31, 2025)
Following the peak in July 2023, the ratio experienced a decline, fluctuating between 7.27 and 8.97 for several quarters before settling at 7.27 in December 2025. This decrease may indicate a lengthening of the payment cycle, potentially due to a deliberate strategy to conserve cash, or challenges in maintaining the previously observed efficiency. The ratio’s decline coincides with an increase in accounts payable, suggesting slower payments to suppliers.
Recent Stabilization
The ratio shows some stabilization in the latter part of the period, with values ranging from 8.18 to 8.53 between March 2024 and June 2025. However, the final reported value of 7.27 indicates a renewed downward trend.
Relationship to Cost of Revenues
The cost of revenues generally increased over the period, from US$6,354 million to US$7,204 million. While the payables turnover ratio fluctuated, its movements do not appear directly correlated with the overall increase in cost of revenues. The ratio’s decline, despite rising costs, suggests a potential shift in payment terms or supplier relationships.

In conclusion, the payables turnover ratio demonstrates a dynamic pattern, with an initial improvement followed by a period of decline. Further investigation into the underlying factors driving these changes, such as payment terms, supplier relationships, and cash management strategies, would be beneficial.

AI Ask an analyst for more


Working Capital Turnover

Thermo Fisher Scientific Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Current assets 28,707 22,295 24,584 23,378 22,137 23,783 25,476 23,640 24,589 23,092 19,995 20,209 25,229 19,299 18,100 18,776
Less: Current liabilities 15,189 14,888 12,718 13,174 13,332 14,601 14,772 13,937 14,012 14,158 14,112 15,884 17,010 11,118 10,997 12,070
Working capital 13,518 7,407 11,866 10,204 8,805 9,182 10,704 9,703 10,577 8,934 5,883 4,325 8,219 8,181 7,103 6,706
 
Revenues 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Short-term Activity Ratio
Working capital turnover1 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Johnson & Johnson 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Merck & Co. Inc. 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Vertex Pharmaceuticals Inc. 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Working capital turnover = (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025) ÷ Working capital
= (12,215 + 11,122 + 10,855 + 10,364) ÷ 13,518 = 3.30

2 Click competitor name to see calculations.


The working capital turnover ratio exhibits considerable fluctuation throughout the observed period. Initially, the ratio demonstrates relative stability, decreasing from 6.13 to 6.03, then declining to 5.40 and 5.46. A significant increase is then observed, peaking at 10.13 before decreasing again over subsequent quarters.

Initial Period (Apr 2, 2022 – Dec 31, 2022)
The working capital turnover ratio begins at 6.13 and experiences a moderate decline to 5.46. This suggests a slight decrease in the efficiency with which working capital is being used to generate revenue during this timeframe. The values remain relatively consistent, indicating a stable, albeit slightly decreasing, operational pattern.
Volatility and Peak (Apr 1, 2023 – Jul 1, 2023)
A substantial increase in the ratio is evident, rising to 10.13. This indicates a marked improvement in the efficiency of working capital utilization. However, this is followed by a rapid decline to 7.40 in the subsequent quarter, suggesting the initial improvement may not have been sustained or was influenced by temporary factors.
Subsequent Decline and Stabilization (Sep 30, 2023 – Dec 31, 2024)
The ratio continues its downward trend, reaching a low of 3.96. It then shows a slight recovery to 4.87. This period demonstrates a general decrease in the efficiency of working capital, although the final value suggests a potential stabilization. The ratio remains below the initial values observed at the beginning of the period.
Recent Fluctuations (Mar 29, 2025 – Dec 31, 2025)
The ratio fluctuates significantly, moving from 4.20 to 3.64, then increasing to 5.90, and finally decreasing to 3.30. This recent volatility suggests increased uncertainty in the company’s operational efficiency. The final value of 3.30 represents the lowest point in the observed period, indicating a substantial decrease in the effectiveness of working capital management.

Overall, the working capital turnover ratio demonstrates a complex pattern of fluctuations. While periods of increased efficiency are observed, a general downward trend is apparent, particularly in the most recent quarters. Further investigation into the underlying drivers of these changes, such as revenue fluctuations and working capital component variations, would be necessary to provide a more comprehensive understanding.

AI Ask an analyst for more


Average Inventory Processing Period

Thermo Fisher Scientific Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Inventory turnover 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Short-term Activity Ratio (no. days)
Average inventory processing period1 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Johnson & Johnson 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Vertex Pharmaceuticals Inc. 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.85 = 75

2 Click competitor name to see calculations.


The average inventory processing period demonstrates a generally decreasing trend over the observed timeframe, with some fluctuations. Initially, the period stood at 94 days, and subsequently decreased to 72 days before experiencing some volatility and concluding at 75 days.

Overall Trend
From April 2022 through December 2023, a consistent downward trend in the average inventory processing period is evident. This suggests increasing efficiency in managing inventory, potentially due to improved supply chain management, more accurate demand forecasting, or successful implementation of inventory reduction strategies. However, this trend plateaus and fluctuates in subsequent periods.
Short-Term Fluctuations
Following the low of 72 days in December 2023, the average inventory processing period increased to 76 days in March 2024, then to 79 days in June 2024, and peaked at 82 days in September 2024. This suggests a temporary slowdown in inventory turnover during that period. The period then decreased to 75 days by December 2025.
Recent Performance
The most recent periods (March 2025 through December 2025) show a slight increase from 75 to 82 days, followed by a decrease back to 75 days. This suggests a potential stabilization of the inventory processing period, or a cyclical pattern related to seasonal demand or supply chain dynamics. The period remains relatively stable compared to the earlier, more pronounced declines.
Correlation with Inventory Turnover
The observed trends in the average inventory processing period align with the inventory turnover ratio. As inventory turnover increased, the processing period decreased, and vice versa. This inverse relationship is expected, as a higher turnover rate indicates inventory is being sold and replenished more quickly.

In summary, the company has generally improved its inventory management efficiency over the analyzed period, as indicated by the decreasing trend in the average inventory processing period. While recent periods show some fluctuation, the metric remains within a relatively narrow range, suggesting a degree of stability in inventory management practices.

AI Ask an analyst for more


Average Receivable Collection Period

Thermo Fisher Scientific Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Receivables turnover 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Short-term Activity Ratio (no. days)
Average receivable collection period1 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Johnson & Johnson 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Vertex Pharmaceuticals Inc. 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.01 = 73

2 Click competitor name to see calculations.


The average receivable collection period exhibited a generally increasing trend over the analyzed timeframe, beginning in April 2022 and concluding in December 2025. While fluctuations occurred, the period lengthened from 70 days to 73 days over the entire period. Initial observations reveal periods of relative stability interspersed with incremental increases.

Initial Period (Apr 2, 2022 – Oct 1, 2022)
The average receivable collection period demonstrated a consistent decrease, moving from 70 days to a low of 63 days. This suggests an improvement in the efficiency of collecting receivables during this six-month period.
Stabilization and Slight Increase (Dec 31, 2022 – Jul 1, 2023)
Following the decline, the collection period stabilized around 66-70 days for four consecutive quarters. A slight increase was observed in the July 1, 2023, reporting period, reaching 67 days.
Further Lengthening (Sep 30, 2023 – Jun 28, 2025)
From September 30, 2023, through June 28, 2025, a more pronounced upward trend emerged. The collection period increased from 70 days to 73 days, with a peak of 74 days recorded on September 27, 2025. This indicates a gradual slowing in the rate at which receivables are being converted into cash.
Final Period (Dec 31, 2025)
The average receivable collection period concluded at 73 days, representing a slight decrease from the peak observed in the prior quarter, but still higher than the period observed in the earlier part of the analyzed timeframe.

Overall, the trend suggests a potential weakening in the company’s ability to efficiently manage its accounts receivable in the later periods. While the increases are relatively modest, continued monitoring of this metric is warranted to identify any underlying causes and potential impacts on cash flow.

AI Ask an analyst for more


Operating Cycle

Thermo Fisher Scientific Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Average inventory processing period 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Average receivable collection period 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Short-term Activity Ratio
Operating cycle1 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Johnson & Johnson 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Vertex Pharmaceuticals Inc. 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 75 + 73 = 148

2 Click competitor name to see calculations.


The operating cycle exhibited a generally decreasing trend over the observed period, with some fluctuations. Initially, the operating cycle stood at 164 days in April 2022, and progressively declined to 142 days by December 2023. Subsequent quarters saw some increases, peaking at 156 days in September 2025, before concluding at 148 days in December 2025. This suggests improvements in the efficiency of converting inventory into cash, though recent periods indicate a potential stabilization or slight lengthening of this cycle.

Average Inventory Processing Period
The average inventory processing period demonstrated a consistent decline from 94 days in April 2022 to a low of 72 days in December 2022. It then stabilized around 76-79 days for several quarters before increasing to 82 days in September 2025. The final reported value for December 2025 was 75 days. This indicates an initial improvement in inventory management, followed by a period of relative consistency, and a slight recent increase.
Average Receivable Collection Period
The average receivable collection period generally decreased from 70 days in April 2022 to 66 days in July 2022, then fluctuated between 63 and 70 days for the remainder of 2022 and throughout 2023. A gradual increase was observed in 2024 and 2025, reaching 74 days in September 2025 and remaining at 73 days in December 2025. This suggests a slight lengthening in the time taken to collect receivables in the more recent periods.

The combined effect of these trends is reflected in the operating cycle. The initial decline in the operating cycle was likely driven by improvements in both inventory management and receivable collection. The recent stabilization and slight increase in the operating cycle suggest that the gains made in these areas may be leveling off, or that external factors are influencing the overall cycle length. Further investigation into the reasons behind the recent fluctuations in both the inventory processing and receivable collection periods would be beneficial.

AI Ask an analyst for more


Average Payables Payment Period

Thermo Fisher Scientific Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Payables turnover 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Short-term Activity Ratio (no. days)
Average payables payment period1 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Johnson & Johnson 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Vertex Pharmaceuticals Inc. 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 7.27 = 50

2 Click competitor name to see calculations.


The average payables payment period exhibited fluctuations over the observed timeframe. Initially, a decreasing trend was apparent, followed by periods of relative stability and subsequent increases.

Overall Trend
The average payables payment period generally decreased from 46 days in April 2022 to a low of 34 days in July 2023. Following this decline, the period stabilized in the mid-30s for several quarters before increasing to 50 days by December 2025. This suggests a potential shift in the company’s payment practices or negotiating power with suppliers towards the end of the period.
Short-Term Fluctuations
A notable decrease occurred between April 2022 and July 2022, dropping from 46 days to 41 days. A further reduction was seen between July 2022 and October 2022, reaching 37 days. The period then increased slightly to 48 days by December 2022 before resuming a downward trend, reaching its minimum in July 2023. A period of relative stability followed from July 2023 through March 2024, fluctuating between 34 and 38 days. The most significant increase occurred between September 2024 (38 days) and December 2025 (50 days).
Recent Performance
The most recent quarters demonstrate a clear upward trend in the average payables payment period. From June 2024 (37 days) to December 2025 (50 days), the period increased by 13 days. This could indicate a deliberate strategy to preserve cash flow, potentially due to changing economic conditions or internal financial goals. Alternatively, it could reflect less favorable payment terms negotiated with suppliers.
Relationship to Payables Turnover
The observed trends in the average payables payment period are inversely related to the payables turnover ratio. As payables turnover increased, the payment period decreased, and vice versa. This relationship is expected, as a higher turnover indicates faster payment to suppliers, resulting in a shorter payment period. The recent decline in payables turnover, concurrent with the increase in the payment period, reinforces this inverse relationship.

AI Ask an analyst for more


Cash Conversion Cycle

Thermo Fisher Scientific Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Average inventory processing period 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Average receivable collection period 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Average payables payment period 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Short-term Activity Ratio
Cash conversion cycle1 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Johnson & Johnson 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Vertex Pharmaceuticals Inc. 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 75 + 7350 = 98

2 Click competitor name to see calculations.


The short-term operating activity of the company, as measured by its cash conversion cycle and component ratios, exhibits fluctuations over the observed period. Generally, the company demonstrates a relatively stable, though variable, ability to convert its investments in inventory and receivables into cash, while managing its payment obligations to suppliers.

Average Inventory Processing Period
The average number of days to process inventory generally decreased from 94 days in April 2022 to 72 days in December 2022. This trend reversed somewhat in subsequent periods, peaking at 82 days in September 2025, before decreasing to 75 days in December 2025. The fluctuations suggest potential changes in inventory management efficiency or shifts in the composition of inventory held. A slight increase is observed in the most recent two quarters.
Average Receivable Collection Period
The average receivable collection period showed a decreasing trend from 70 days in April 2022 to 66 days in July 2022, stabilizing around 67-70 days through September 2023. A gradual increase is then observed, reaching 74 days in September 2025, before decreasing slightly to 73 days in December 2025. This indicates a potential lengthening in the time taken to collect payments from customers, which could be due to changes in credit policies or customer payment behavior.
Average Payables Payment Period
The average payables payment period demonstrated considerable variability. It decreased from 46 days in April 2022 to 34 days in July 2023, before increasing to 41 days in December 2023 and 50 days in December 2025. This suggests the company has adjusted its payment terms with suppliers, potentially to optimize cash flow or take advantage of supplier discounts. The recent increase may indicate a strategic decision to extend payment terms.
Cash Conversion Cycle
The cash conversion cycle decreased from 118 days in April 2022 to a low of 97 days in December 2022. It then increased to 112 days in July 2023, before decreasing again to 101 days in December 2023. The cycle experienced another increase, peaking at 112 days in September 2025, and then decreased to 98 days in December 2025. The cycle’s movements are a composite of the trends in the individual component ratios. The recent decrease suggests improved efficiency in managing working capital, although the cycle remains relatively high, indicating a substantial period where cash is tied up in operations.

Overall, the company’s cash conversion cycle demonstrates sensitivity to changes in inventory management, receivable collection, and payable payment practices. Continued monitoring of these ratios is recommended to identify potential areas for improvement in working capital management and to assess the impact of strategic decisions on cash flow.

AI Ask an analyst for more